• Home
  • About
  • Webcasts
  • ‘Enforcement 40’ for 2020
  • Enforcement Hall of Fame
  • Contact
Securities Docket
Ankura 480x60
  • Class Actions
  • Criminal
  • Global
  • People
  • SD Insider
  • SEC
  • Video
  • Subscribe by email
  • Subscribe
Browse: Home / 2010 / February / 25 / SEC and DOJ Expand Eli Lilly FCPA Probes

SEC and DOJ Expand Eli Lilly FCPA Probes

By Amanda Harding on February 25, 2010, 11:47 am

The SEC and DOJ have expanded their investigations of Eli Lilly & Co.’s compliance with the Foreign Corrupt Practices Act. The Wall Street Journal reports that the investigation now includes Lilly’s activities in additional countries. The SEC began investigating Lilly in 2003 The SEC initially notified Lilly in 2003 that it was probing whether its Polish unit had violated the Foreign Corrupt Practices Act

Lilly filed a regulatory document on Monday stating that authorities have recently increased this type of enforcement against drug companies. According to the Wall Street Journal, enforcing the FCPA against drug companies can be difficult because many health systems are government-run. As a result, employees at drug companies who give items of value to doctors and health ministry officials of state-run health systems may violate the FCPA.

Read the Wall Street Journal article

Blog Widget by LinkWithin

Posted in Criminal, SEC | Tagged FCPA, Investigations

« Previous Next »

‘Enforcement 40’ for 2020

Securities-Docket_Medium-Rectangle_CaseStudyArrow

Our Sponsors

Securities-Docket_260x125_14Sec Ankura 260x125

Join Us On LinkedIn

Join the Securities Litigation and Enforcement Group on LinkedIn

Archives

Copyright © 2021 Securities Docket.

Powered by WordPress and Hybrid.